Jou(RNA)l – CureVac’s Newsroom

This section contains the latest press releases and media reports about CureVac.

  • 17-11-13 / Press Release / CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

    CureVac’s mRNA technology accessed to express Cas9 for in vivo liver-targeted therapies

    Read more
  • 17-11-06 / Press Release / 5th International mRNA Health Conference Highlights Rapid Clinical Progress and Cross-Industry Collaboration

    TÜBINGEN / BERLIN Germany, November 6, 2017 – The International mRNA Health Conference, the premier meeting destination for professionals and...

    Read more
  • 17-10-29 / Press Release / CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics

    TÜBINGEN, Germany, October 30, 2017 – CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of RNA-based drugs, today...

    Read more
  • 17-10-27 / Press Release / CureVac Initiates Phase I Clinical Trial of RNAdjuvant® Candidate as Intratumoral Therapy for Solid Tumors

    Study to evaluate safety, tolerability and immunomodulating effects of CV8102

    Read more
  • 17-10-23 / Press Release / Publication in npj Vaccines Demonstrates CureVac’s RNActive® Vaccine is Superior to Licensed Vaccines

    Data indicate that specifically optimized mRNA vaccines constitute a potent platform for human prophylaxis

    Read more
  • 17-10-20 / Media Report / Endpoints News

    "Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines"

    Read more
  • 17-10-18 / Media Report / FierceBiotech

    "Lilly, CureVac pen $1.8B mRNA cancer vaccine deal"

    Read more
  • 17-10-18 / Media Report / Financial Times

    "Eli Lilly invests in Germany’s CureVac in cancer vaccine drive"

    Read more
  • 17-10-18 / Press Release / Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

    Immuno-oncology collaboration aims to develop up to five cancer vaccines that target neoantigens across multiple tumor types / CureVac to receive...

    Read more
  • 17-10-12 / Media Report / Nature Biotechnology

    "A successful founder off the beaten path"

    Read more
  • 17-09-11 / Media Report / BIOspektrum

    "Molekulare Medizin - mRNA-basierte Therapien für eine passive Immunisierung"

    Read more
  • 17-08-15 / Press Release / Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors

    Data validate the strength of CureVac’s RNAntibody® technology to produce high and sustained levels of antibody production in a variety of disease...

    Read more
  • 17-07-31 / Press Release / 5th International mRNA Health Conference to Showcase Tremendous Advances in the Development of mRNA Drugs

    Global Thought Leaders Convene to Share Progress in Research and Development of mRNA Products Believed to be the Next Evolution in Human Medicine

    Read more
  • 17-07-27 / Media Report / Handelsblatt Global

    "Vaccine research - Rabid about Curevac"

    Read more
  • 17-07-26 / Press Release / CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

    Data from phase I clinical trial of CureVac’s RNActive® prophylactic vaccine technology in rabies demonstrates for the first time an induction of...

    Read more
  • 17-07-20 / Press Release / CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies

    Patent covers Composition of Matter and Methods of Treatment for vaccine/inhibitor combination for the prevention or treatment of cancer and...

    Read more
  • 17-06-26 / Press Release / CureVac Expands GMP Production Capacities for RNA Products

    Supply for Full RNA Clinical Pipeline and Later Commercialization Secured

    Read more
  • 17-06-13 / Press Release / CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines

    Patents granted for mRNA-based RSV vaccines as well as for vaccination of infants / newborns and elderly with mRNA-based vaccines such as Flu

    Read more
  • 17-05-19 / Press Release / CureVac to Present at Upcoming International Investor Conferences

    TÜBINGEN, Germany, May 19, 2017 – CureVac AG, the most clinically advanced mRNA company, today announced that the company will present at two upcoming...

    Read more
  • 17-05-02 / Press Release / CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary

    TÜBINGEN, Germany, May 2, 2017 – CureVac AG, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based therapies, today announced...

    Read more
  • 17-03-17 / Media Report / Handelsblatt Global

    "Top Innovators - Germany's Quiet Visionaries, Part X"

    Read more
  • 17-02-27 / Media Report / Nature Biotechnology

    "The 'anti-hype' vaccine"

    Read more
  • 17-02-25 / Media Report / BioCentury

    "mRNA test kitchens - Where biopharma is betting on mRNA"

    Read more
  • 17-01-23 / Media Report / European Biotechnology

    "Biotech CEOs advise EU on breakthrough innovations"

    Read more
  • 17-01-20 / Press Release / CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group

    TÜBINGEN, Germany, January 20, 2017 – CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today...

    Read more
  • 17-01-19 / Media Report / Handelsblatt Global Edition

    "Bill Gates: We Need To Be Prepared For Epidemics"

    Read more
  • 17-01-17 / Media Report / idw - Informationsdienst Wissenschaft (German)

    "Wirkmechanismus eines neuartigen RNA-Impfverstärkers aufgeklärt – Kooperation mit CureVac"

    Read more
  • 17-01-11 / Press Release / CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference

    SAN FRANCICSO/TÜBINGEN (Germany), January 11, 2017 – CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based...

    Read more
  • 16-12-28 / Press Release / CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017

    TÜBINGEN, Germany, December 28, 2017 – CureVac, a clinical-stage biopharma-ceutical company pioneering the field of mRNA-based technology, announced...

    Read more
  • 16-12-05 / Press Release / Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy, Demonstrates Equal responsiveness of blood cells from Both Hepatocellular Carcinoma (HCC) Patients and Healthy Subjects to the RNA-based adjuvant
    • For the first time, evidence suggests the same vaccine formulation (RNAdjuvant®) may elicit similar potency in both cancer patients and healthy...
    Read more
  • 16-11-08 / Press Release / CureVac Secures an Additional $29.5 Million From Two New Investors

    Baden-Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte and Landeskreditbank Baden-Württemberg invest in CureVac‘s development of...

    Read more
  • 16-11-08 / Press Release / CureVac Receives Broad Patent for RNAntibody® Technology

    CureVac AG today announced that it has been granted a patent (patent No. EP2101823) by the European Patent Office providing broad patent protection...

    Read more
  • 16-11-02 / Media Report / GEN (Genetic Engineering & Biotechnology News)

    "Enabling the Body to Manufacture Its Own Medicine"

    Read more
  • 16-10-11 / Press Release / CureVac Appoints Pierre Kemula as Chief Financial Officer

    Mr. Kemula will join CureVac’s management board and will be responsible for leading the company’s financial and capital markets activities.

    Read more
  • 16-08-08 / Media Report / Deutsches Ärzteblatt (German)

    "HIV-Impfung: Nicht in Sicht, aber in Arbeit"

    Read more
  • 16-07-14 / Press Release / Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines

    CureVac AG today announced that a study of its RNActive® technology was published in the renowned, peer-reviewed journal Vaccine

    Read more
  • 16-05-23 / Media Report / The Wall Street Journal

    "Ebola, Zika Push Global Health Leaders on Disease Fight, Bill & Melinda Gates Foundation CEO Says"

    Read more
  • 16-04-13 / Media Report / Handelsblatt (German)

    "Deutschland braucht mehr Erfolgsstorys"

    Read more
  • 16-04-13 / Media Report / Süddeutsche Zeitung (German)

    "Das Geschäft machen andere"

    Read more
  • 16-04-12 / Media Report / Stuttgarter Zeitung (German)

    "Deutsche Biotech-Branche schöpft Potenzial nicht aus"

    Read more
  • 16-03-30 / Press Release / CureVac Appoints Leading Experts to its Scientific Advisory Board

    CureVac today announced the expansion of its external Scientific Advisory Board (SAB) to guide the company in this important period of extensive...

    Read more
  • 16-03-26 / Media Report / DER SPIEGEL (German)

    "Einhorn aus Tübingen - Curevac gilt als größte Hoffnung der deutschen Biotech-Szene..."

    Read more
  • 16-03-18 / Press Release / CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion

    CureVac today announced the appointment of three seasoned industry experts to its supervisory board

    Read more
  • 16-02-18 / Press Release / CureVac announces “MERAN” has been approved by the World Health Organization as suffix for mRNA drug substances

    CureVac AG today announced that the World Health Organization (WHO) has approved “MERAN” as a suffix for mRNA drug substances

    Read more
  • 16-01-06 / Press Release / CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference

    CureVac presenting at the leading healthcare conference following numerous financial, clinical and corporate milestones

    Read more
  • 16-01-05 / Media Report / LaBiotech

    "Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?"

    Read more
  • 15-12-16 / Media Report / Handelsblatt (German)

    "Es geht uns nicht ums Geldverdienen"

    Read more
  • 15-12-13 / Media Report / Frankfurter Allgemeine Zeitung (German)

    "Nur mal schnell die Welt retten"

    Read more
  • 15-11-13 / Media Report / Rhein-Neckar-Zeitung (German)

    "Mannheim: Roche offen für Partnerschaften"

    Read more
  • 15-11-03 / Press Release / CureVac raises $110 Million in a private placement

    Further investment for development of mRNA products

    Read more
  • 15-11-03 / Media Report / Handelsblatt (German)

    "Curevac erhält Finanzspritze - 100 Millionen Euro für den Biotech-Star"

    Read more
  • 15-11-03 / Media Report / DowJones VENTUREWIRE

    "CureVac Amasses $110M for Messenger RNA Therapeutics"

    Read more
  • 15-11-02 / Media Report / FierceBiotech

    "Gates, Hopp back $110M megaround for CureVac's mRNA work"

    Read more
  • 15-09-10 / Media Report / Xconomy

    "CureVac Opens up an mRNA Hub in Moderna’s Cambridge Backyard"

    Read more
  • 15-09-10 / Press Release / IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates

    Novel HIV immunogens to be delivered via novel mRNA platform

    Read more
  • 15-09-10 / Press Release / CureVac Establishes U.S. Operations in Cambridge, MA

    Company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines

    Read more
  • 15-09-02 / Media Report / Süddeutsche Zeitung (German)

    "Pioniere der Biotechnologie"

    Read more
  • 15-08-30 / Media Report / Frankfurter Allgemeine Sonntagszeitung / faz.net (German)

    "Milliarden für ein Molekül"

    Read more
  • 15-08-25 / Media Report / Deutsche Welle (Video)

    "Cash injection spurs vaccination hopes"

    Read more
  • 15-08-04 / Press Release / CureVac & Bill & Melinda Gates Foundation - Collaboration to Develop mRNA Vaccines Expands

    Third Program in Collaboration with Foundation to Develop Vaccine against Respiratory Syncytial Virus (RSV) on the basis of CureVac’s Proprietary...

    Read more
  • 15-07-23 / Media Report / EP Vantage

    "Vantage Point – The messenger comes calling"

    Read more
  • 15-07-13 / Media Report / BIOPRO (German)

    "CureVac und Boehringer Ingelheim - zwei starke Partner im Kampf gegen Krebs"

    Read more
  • 15-07-07 / Press Release / CureVac Announces Phase I/IIa Clinical Study Data

    Publication of clinical data of mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer

    Read more
  • 15-06-24 / Press Release / CureVac Announces Study Publication in Molecular Therapy Demonstrating Wide-Ranging Benefits of Sequence-Optimized, Unmodified mRNAs

    Peer-Reviewed Data Indicate that CureVac’s RNArt® Technology Can Produce Therapeutically Relevant Protein Levels

    Read more
  • 15-03-05 / Press Release / The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology

    Equity investment and additional funding of several vaccine development programs

    Read more

Your contact

Verena Lauterbach
Senior Manager Communications
T: +49 7071 9883 1756
contact via e-mail

CureVac's Scientific Publications

can be found here...